Kim A. Reiss, MD

Hannah J. Glover, Farahnaz Islam, Stephanie Thiede, Seung Won Hyun, Riccardo Miotto, Samuel Heilbroner, Zachary Rivers, Victoria L. Chiou, Timothy J. Taxter, Michelle M. Stein, Chani Stossel, Kim A. Reiss, Chithra Sangli, Charles T. Koyias, Halla Nimeiri, Diane M. Simeone, Talia Golan AI-driven RNA-based homologous recombination deficiency algorithm to predict first-line platinum response in metastatic pancreatic cancer , ASCO Annual Meeting, Chicago, IL: 2026

Sean O'Connor, Nicholas Seewald, William J. Chapin. Abigail Doucette, Catherine Blaha, Kim A. Reiss Evaluation of the impact of GLP-1 receptor agonists (RAs) on stage of PDAC diagnosis: A retrospective matched cohort study , ASCO Annual Meeting, Chicago, IL: 2026

*Vincent Chung, Katherine A. Guthrie, Michael Jon Pishvaian, Andrew Lowy, Davendra Sohal, Sarah Colby, Kim A. Reiss, Gazala Khan, Rafael Winograd, Jeffrey Meyerhardt, Eileen O'Reilly, E. Gabriela Chiorean, Philip Philip SWOG2001: Olaparib Plus Pembrolizumab Versus Olaparib Alone as Maintenance Therapy in Metastatic Pancreatic Cancer With Germline BRCA1/2 Mutations , Rapid Oral Abstract Session, ASCO 2026, Chicago, IL : 2026

Maheswari Senthil, Sung C. Hong, Nataliya V. Uboha, Farshid Dayyani, Xin Yao, Mehraneh D. Jafari, Ibrahim Nassour, Kim A. Reiss, Shishir K. Maithel, Jordan Berlin A randomized phase II/III trial of intraperitoneal paclitaxel plus systemic treatment vs systemic treatment alone in gastric carcinomatosis: STOPGAP II—ECOG-ACRIN EA2234 , ASCO Annual Meeting, Chicago, IL: 2026

William J. Chapin, Nadia Cenou, Devora Delman, Jennifer R. Eads, Michele Manley, Kim A. Reiss, Megan Sackey, Ursina R. Teitelbaum, Jennifer Walsh, Gregory L. Beatty, Mark H. O'Hara Phase II trial of pembrolizumab in combination with odetiglucan for patients with metastatic colorectal adenocarcinoma with liver-predominant disease , ASCO Annual Meeting, Chicago, IL: 2026

Kim A. Reiss, Mingyi Xia, Mwangala Akamandisa, Kurt D’Andrea, Brad Wubbenhorst, Christopher J. Lord, Stephen J. Pettitt, Andrew N.J. Tutt, Ch.B., Ph.D5, Timothy J. Brown, MD, Mark H. O’Hara, MD, Charles Schneider, Ursina Teitelbaum, Zain Hannan, Ryan Hood, Rashmi Tondon, Robert H Vonderheide, MD, DPhil, Susan M. Domchek, MD, and Katherine L. Nathanson, MD Long-Term Outcomes of BRCA+ or PALB2+ Pancreatic Cancer Patients Treated with Maintenance Rucaparib , JAMA Oncology: 2026

Alison M. Schram, Olumide B. Gbolahan, Cindy Neuzillet, Dirk Arnold, Antoine Hollebecque, Richard Greil, Mohammed Najeeb Al Hallak Jordi Rodon Ahnert, Kim A. Reiss, Paul F. La Porte, Tormod Kyrre Guren, Carolyn E. Ragsdale, Fiona Garner, Alejandro D. Ricart, Shola Adeyemi, 13 Christoph Springfeld Continued zenocutuzumab treatment beyond progression in patients with NRG1+ pancreatic cancer and cholangiocarcinoma: analysis from the phase 2 eNRGy trial , ASCO GI 2026, San Francisco, CA: 2026

Alison M. Schram, Olumide B. Gbolahan, Cindy Neuzillet, Dirk Arnold, Antoine Hollebecque, Richard Greil, Mohammed N. Al Hallak, Jordi Rodon Ahnert, Kim A. Reiss, Paul La Porte, Tormod Kyrre Guren, Carolyn E. Ragsdale, Fiona Garner, Alejandro D. Ricart, Shola Adeyemi, Christoph Springfeld Continued zenocutuzumab treatment beyond progression in patients with NRG1+ pancreatic cancer and cholangiocarcinoma: Analysis from the phase 2 eNRGy trial , ASCO GI, San Francisco, CA: 2026

John C McVey, Max M Wattenberg, Heather Coho, Kayjana Infante, Kelly Markowitz, Devora Delman, Cynthia Clendenin, Emma E Furth, Rashmi Tondon, Ben Z Stanger, Robert H Vonderheide, Kim A Reiss, Gregory L Beatty Sequential platinum and PARP Inhibition enhances PD1 immunotherapy efficacy in murine Brca2 mutated pancreatic cancer , Scientific Reports: 2026

Ben Boursi, MD; Zakary L. Kolkey, MD; Kim Anna Reiss, MD; Mark H. O’Hara, MD; William Chapin, MD, MSCE Comparative effectiveness of oxaliplatin or irinotecan rechallenge/reintroduction vs standard third-line therapies in patients with metastatic colorectal cancer , ASCO GI 2026, San Francisco, CA: 2026